ARCHIVES

DCPC Faces Huge Out Year Costs Of Four Trials

This article is from The Cancer Letter archive.

Vol. 17 No. 07 | February 15, 1991

Download PDF Visit The Full Archive

Related Articles

NIH offers student loan repayment program, deadline is Dec. 31.

November 21, 2003

FDA Expands Nexavar Indication To Include Thyroid Cancer

December 27, 2013

Survival Rates Same For Two Treatments For Eye Cancer: Radiation Or Removal

July 27, 2001

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

January 25, 2002

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004

Leukemia & Lymphoma Society offers translational research grants.

October 24, 2003